Loading
Pacific Edge Limited Stock: price and insider trades · Australia
Pacific Edge Limited: what insiders have been doing
Only a handful of insider records exist for Pacific Edge Limited, the last one from 24 August 2026, too few to describe a trend. Source: insider filings from ASX. Past trades are no guide to future returns.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 19,173 of 24,161 companies
31.4
score / 100
Value13
Quality50
FCF yld-14%
Earn yld-15%
EV/EBITDA·
ROE-195%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
A$0.19
Analyst consensus
Income statement
RevenueA$11.5M
Gross profitA$11.5M100% margin
EBITDA-A$37M-322% margin
Net income-A$35.8M-275.0% margin
Valuation
P/Book23.6x
Beta0.84
Balance sheet & cash
Market capA$236M
Total debtA$1.3M
Free Cash Flow-A$32.1M
Debt / Equity12%
Profitability & ownership
ROE-194.7%
ROA-83.2%
% insiders19.7%
% institutions30.2%
Last declaration on 24 August 2026
About Pacific Edge Limited
Pacific Edge Limited is a company listed on the Australian Securities Exchange, specializing in the development of diagnostic tests for cancer. It focuses on improving patient outcomes through innovative health solutions.
